Cargando…
A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
As a potent lymphocyte activator, interleukin-2 (IL-2) is an FDA-approved treatment for multiple metastatic cancers. However, its clinical use is limited by short half-life, low potency, and severe in vivo toxicity. Current IL-2 engineering strategies exhibit evidence of peripheral cytotoxicity. Her...
Autores principales: | Hsu, Eric J., Cao, Xuezhi, Moon, Benjamin, Bae, Joonbeom, Sun, Zhichen, Liu, Zhida, Fu, Yang-Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119481/ https://www.ncbi.nlm.nih.gov/pubmed/33986267 http://dx.doi.org/10.1038/s41467-021-22980-w |
Ejemplares similares
-
Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8(+) T cells
por: Wang, Xue, et al.
Publicado: (2023) -
Potent Chlorambucil-Platinum(IV) Prodrugs
por: Aputen, Angelico D., et al.
Publicado: (2022) -
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
por: Bronte, Vincenzo, et al.
Publicado: (2005) -
MEPicides: potent antimalarial prodrugs targeting isoprenoid biosynthesis
por: Edwards, Rachel L., et al.
Publicado: (2017) -
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes
por: Caruana, Ignazio, et al.
Publicado: (2015)